Product Description
A recombinant human-derived monoclonal antibody targeting the tumor cell-protective protein complement factor H (CFH), with potential immunomodulatory and antineoplastic activities. Upon administration, the anti-CFH monoclonal antibody GT103 targets and binds specifically to a conformationally distinct epitope within a specific crucial functional domain of CFH bound on tumor cells. This activates the complement cascade, triggers complement dependent cytotoxicity and leads to the destruction of the tumor cells. In addition, GT103 modulates the adaptive anti-tumor immune response, thereby reducing the number of immune suppressive T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor. This may potentially provide long-term anti-tumor immunity and protection. CFH, the major regulator of the central complement protein C3b in the alternative pathway of complement activation, normally prevents cells from destruction by the immune system. CFH may play a key role in protection against complement-mediated lysis in various cancer cells. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cfh-monoclonal-antibody-gt103)
Mechanisms of Action: CFH Antagonist
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jeffrey Clarke
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PRO00109146 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2026-01-01 |